Tags

Type your tag names separated by a space and hit enter

Prenatal diagnosis of mitochondrial fatty acid oxidation defects.
Prenat Diagn. 1996 Feb; 16(2):117-24.PD

Abstract

Amniocytes isolated from two pregnancies at risk for fatty acid oxidation defects were incubated with stable isotopically labelled palmitate, in the presence of L-carnitine, to probe that pathway. The labelled acylcarnitines were then quantitated using tandem mass spectrometry. Amniocytes from a pregnancy at risk for medium-chain acyl-CoA dehydrogenase (MCAD) deficiency produced a characteristic acylcarnitine profile with increased levels of octanoylcarnitine and decanoylcarnitine, indicative of MCAD deficiency. DNA analysis confirmed that the fetus was homozygous for the MCAD A985G mutation. Acylcarnitine and DNA analysis of the infant's blood obtained post-partum confirmed MCAD deficiency. Amniocytes from a pregnancy at risk for an unspecified fat oxidation defect produced increased levels of long-chain acylcarnitines consistent with a deficiency in very-long-chain acyl-CoA dehydrogenase (VLCAD). Measurements of the enzymatic activity confirmed VLCAD deficiency in amniocytes. Acylcarnitine profiles of the infant's blood obtained post-partum in addition to enzyme activities measured in fibroblasts confirmed VLCAD deficiency. The successful prenatal diagnosis of VLCAD and MCAD deficiencies using in vitro probes of fatty acid oxidation in fibroblasts suggests that this approach can potentially recognize many mitochondrial fatty acid oxidation defects even if no prior diagnosis is determined in the family at risk.

Authors+Show Affiliations

Metabolic Disease Center, Baylor University Medical Center, Dallas, TX 75246, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

8650121

Citation

Nada, M A., et al. "Prenatal Diagnosis of Mitochondrial Fatty Acid Oxidation Defects." Prenatal Diagnosis, vol. 16, no. 2, 1996, pp. 117-24.
Nada MA, Vianey-Saban C, Roe CR, et al. Prenatal diagnosis of mitochondrial fatty acid oxidation defects. Prenat Diagn. 1996;16(2):117-24.
Nada, M. A., Vianey-Saban, C., Roe, C. R., Ding, J. H., Mathieu, M., Wappner, R. S., Bialer, M. G., McGlynn, J. A., & Mandon, G. (1996). Prenatal diagnosis of mitochondrial fatty acid oxidation defects. Prenatal Diagnosis, 16(2), 117-24.
Nada MA, et al. Prenatal Diagnosis of Mitochondrial Fatty Acid Oxidation Defects. Prenat Diagn. 1996;16(2):117-24. PubMed PMID: 8650121.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prenatal diagnosis of mitochondrial fatty acid oxidation defects. AU - Nada,M A, AU - Vianey-Saban,C, AU - Roe,C R, AU - Ding,J H, AU - Mathieu,M, AU - Wappner,R S, AU - Bialer,M G, AU - McGlynn,J A, AU - Mandon,G, PY - 1996/2/1/pubmed PY - 2000/6/20/medline PY - 1996/2/1/entrez SP - 117 EP - 24 JF - Prenatal diagnosis JO - Prenat. Diagn. VL - 16 IS - 2 N2 - Amniocytes isolated from two pregnancies at risk for fatty acid oxidation defects were incubated with stable isotopically labelled palmitate, in the presence of L-carnitine, to probe that pathway. The labelled acylcarnitines were then quantitated using tandem mass spectrometry. Amniocytes from a pregnancy at risk for medium-chain acyl-CoA dehydrogenase (MCAD) deficiency produced a characteristic acylcarnitine profile with increased levels of octanoylcarnitine and decanoylcarnitine, indicative of MCAD deficiency. DNA analysis confirmed that the fetus was homozygous for the MCAD A985G mutation. Acylcarnitine and DNA analysis of the infant's blood obtained post-partum confirmed MCAD deficiency. Amniocytes from a pregnancy at risk for an unspecified fat oxidation defect produced increased levels of long-chain acylcarnitines consistent with a deficiency in very-long-chain acyl-CoA dehydrogenase (VLCAD). Measurements of the enzymatic activity confirmed VLCAD deficiency in amniocytes. Acylcarnitine profiles of the infant's blood obtained post-partum in addition to enzyme activities measured in fibroblasts confirmed VLCAD deficiency. The successful prenatal diagnosis of VLCAD and MCAD deficiencies using in vitro probes of fatty acid oxidation in fibroblasts suggests that this approach can potentially recognize many mitochondrial fatty acid oxidation defects even if no prior diagnosis is determined in the family at risk. SN - 0197-3851 UR - https://www.unboundmedicine.com/medline/citation/8650121/Prenatal_diagnosis_of_mitochondrial_fatty_acid_oxidation_defects_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0197-3851&date=1996&volume=16&issue=2&spage=117 DB - PRIME DP - Unbound Medicine ER -